Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 257 clinical trials
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease

participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.

mental state examination
mild cognitive impairment
cognitive impairment
positron emission tomography
amyloid
  • 10 views
  • 28 May, 2022
  • 10 locations
Global Prevalence of ATTR-CM in Participants With HFpEF

This study is a global, multi-center study designed to estimate the global prevalence of transthyretin amyloid cardiomyopathy (ATTR-CM) within a clinically at risk population [participants with

  • 0 views
  • 16 Jun, 2022
  • 25 locations
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE)

A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD. The planned number of

amyloid
dementia
positron emission tomography
  • 1 views
  • 08 Jun, 2022
  • 14 locations
The Swedish BioFINDER 2 Study (BioFINDER2)

is used e.g. to characterize the role of beta-amyloid pathology in early diagnosis of Alzheimer's disease (AD) using amyloid-PET (18F-Flutemetamol) and A analysis in cerebrospinal fluid samples. The

psychiatric disorders
vascular disease
alzheimer's disease
amyloid
cancer
  • 178 views
  • 25 Feb, 2022
  • 1 location
Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary

mild cognitive impairment
cognitive impairment
alzheimer's disease
amyloid
amyloidosis
  • 3709 views
  • 16 Jun, 2022
  • 28 locations
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ)

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 weeks. Approximately 1083 participants will be randomized (1:1:1) to receive either placebo, 50 mg tablets of simufilam, or 100 mg tablets of simufilam, twice daily, for 76 weeks. Clinic …

alzheimer's disease
mini-mental state examination
dementia
  • 9 views
  • 17 Jun, 2022
  • 48 locations
Blood-based Biomarkers for Diagnosis of Alzheimer's

Alzheimer's disease (AD) may currently be diagnosed using molecular biomarkers in cerebrospinal fluid (CSF) and/or positron emission tomography (PET). These diagnostic procedures are highly accurate, but the high cost and low availability hamper their feasibility. Recently, ultrasensitive blood tests predicting Alzheimer pathologies in the brain have been developed. These tests …

cognitive impairment
neurodegenerative disorders
positron emission tomography
cognitive decline
dementia
  • 0 views
  • 13 Jun, 2022
  • 1 location
Non-ischemic Preservation of the Donor Heart in Heart Transplantation

The study intends to compare standard ischemic cold static storage (ICSS) of retrieved hearts intended to be transplanted, to non-ischemic heart preservation (NIHP) in a randomized clinical multicentre trial. The primary hypothesis is that the non-ischemic hypothermic cardioplegic preservation (NIHP) is safe and superior to ischemic cold static storage (ICSS) …

heart transplant
lupus
heart disease
heart transplantation
organ transplantation
  • 0 views
  • 09 Mar, 2021
  • 9 locations
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU001 (DIAN-TU)

The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.

mild cognitive impairment
cognitive impairment
mild dementia
positron emission tomography
alzheimer's disease
  • 3206 views
  • 30 Jan, 2022
  • 28 locations
GLP-1 and Hyperoxia for Organ Protection in Heart Surgery (GLORIOUS)

Patients undergoing open heart surgery are at risk of suffering damage to the heart, brain and kidneys. This study is designed as a 2-by-2 randomized clinical trial with the purpose of investigating the organ protective effects of the glucagon-like-peptide-1 (GLP-1) agonist Exenatide versus placebo and restrictive versus liberal oxygenation during …

byetta
bypass graft
percutaneous coronary intervention
glp-1
heart disease
  • 40 views
  • 27 Jan, 2022
  • 1 location